Anne-laure L. Cazeau

Bordeaux, 33000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Bone Uptake in Prostate Cancer Patients: Diagnostic Performances of PSMA-RADS v1.0, Clinical, Biological, and 68 Ga-PSMA-11 PET Features to Predict Metastasis After Biochemical Recurrence.

Bone Uptake in Prostate Cancer Patients: Diagnostic Performances of PSMA-RADS v1.0, Clinical, Biological, and 68 Ga-PSMA-11 PET Features to Predict Metastasis After Biochemical Recurrence.

Journal: Clinical nuclear medicine

Published: May 11, 2022

Diagnostic accuracy and clinical impact of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in Positron Emission Tomography - Computed Tomography (PET-CT)-positive mediastinal lymphadenopathies in patients with thoracic or extra-thoracic malignancies.

Diagnostic accuracy and clinical impact of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in Positron Emission Tomography - Computed Tomography (PET-CT)-positive mediastinal lymphadenopathies in patients with thoracic or extra-thoracic malignancies.

Journal: Clinics and research in hepatology and gastroenterology

Published: November 18, 2021

Impact of 18 FDG- PET CT in the Management of Muscle Invasive Bladder Cancer.

Impact of 18 FDG- PET CT in the Management of Muscle Invasive Bladder Cancer.

Journal: Clinical genitourinary cancer

Published: August 16, 2021

Single-Center Experience of Focal Thermo-Ablative Therapy After Pelvic Radiotherapy for In-Field Prostate Cancer Oligo-Recurrence.

Single-Center Experience of Focal Thermo-Ablative Therapy After Pelvic Radiotherapy for In-Field Prostate Cancer Oligo-Recurrence.

Journal: Frontiers in oncology

Published: May 14, 2021

Diffusion-weighted MRI and PET/CT reproducibility in epithelial ovarian cancers during neoadjuvant chemotherapy.

Diffusion-weighted MRI and PET/CT reproducibility in epithelial ovarian cancers during neoadjuvant chemotherapy.

Journal: Diagnostic and interventional imaging

Published: February 02, 2021

From palliative to curative intent: PET/CT findings in the light of breast cancer intrinsic subgroup.

From palliative to curative intent: PET/CT findings in the light of breast cancer intrinsic subgroup.

Journal: Tumori

Published: October 25, 2019

Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples.

Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples.

Journal: PloS one

Published: October 15, 2018

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.

Journal: BMC cancer

Published: June 14, 2017

Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts

Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts

Journal: Bulletin du cancer

Published: April 27, 2017

Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.

Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.

Journal: British journal of haematology

Published: January 21, 2017

Role of 18F-FDG PET/CT in Posttreatment Evaluation of Anal Carcinoma.

Role of 18F-FDG PET/CT in Posttreatment Evaluation of Anal Carcinoma.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: October 12, 2016

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Journal: The Lancet. Haematology

Published: July 19, 2016

Showing 1-12 of 19

Last Updated: 09/26/2026